HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

CanSino Biologics (6185.HK) - Will the COVID-19 Vaccine Be the Turning Point?

Industry Report - Insights on China Biological Drug Market

Bio-Thera Solutions (688177.CH) - What's Next for Bio-Thera After R&D Setbacks and Years of Losses?

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

<p><a href="https://www.smartkarma.com/entities/china-medical-system-holdings" target="_blank" data-smartkarma-citation="entities:18736:1" rel="noopener">China Medical System (867 HK)</a>(CMS) recently performed very well. Last week, its stock priced increased about 23%, which was mainly driven by the positive outlook of its business. Meanwhile, the Company announced the annual results for the year ended 31 December 2020. According to the financial reports, turnover was up 14.4% to RMB6,946.0 million (2019: RMB6,073.6 million), which was mainly due to the overall increase in sales of various products. Gross profit was up 12.9% to RMB5,134.2 million (2019: RMB4,546.3 million); Profit for the year was up 30.7% to RMB2,555.7 million (2019: RMB1,955.7 million), which was above market expectation. However, besides the growth, there are some concerns on its star product PLENITY, an orally-administered weight management product.</p>

China Medical System (867 HK)(CMS) recently performed very well. Last week, its stock priced increased about 23%, which was mainly driven by the positive outlook of its business. Meanwhile, the Company announced the annual results for the year ended 31 December 2020. According to the financial reports, turnover was up 14.4% to RMB6,946.0 million (2019: RMB6,073.6 million), which was mainly due to the overall increase in sales of various products. Gross profit was up 12.9% to RMB5,134.2 million (2019: RMB4,546.3 million); Profit for the year was up 30.7% to RMB2,555.7 million (2019: RMB1,955.7 million), which was above market expectation. However, besides the growth, there are some concerns on its star product PLENITY, an orally-administered weight management product.

China Medical System (867.HK) - The Concerns Are On "PLENITY"